Anguilla Healthcare Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Anguilla Healthcare Digest.

Press releases published on March 31, 2026

Mar. 31, 2026

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Indeterminate GlobeNewswire

Mar. 31, 2026

CancerVax Reports Successful Initial Mouse Study with Breakthrough Results

Indeterminate GlobeNewswire

Mar. 31, 2026

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Indeterminate GlobeNewswire

Mar. 31, 2026

Standing Ovation lève $34,2 M pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation, une réponse souveraine et durable à l’explosion de la demande en protéines

Indeterminate GlobeNewswire

Mar. 31, 2026

Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate

Indeterminate GlobeNewswire

Mar. 31, 2026

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Indeterminate GlobeNewswire

Mar. 31, 2026

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen

Indeterminate GlobeNewswire

Mar. 31, 2026

ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones

Indeterminate GlobeNewswire

Mar. 31, 2026

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Indeterminate GlobeNewswire

Mar. 31, 2026

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte

Indeterminate GlobeNewswire

Mar. 31, 2026

BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health

Indeterminate GlobeNewswire

Mar. 31, 2026

Neuro Serge Claims Evaluated: Dangers Emerge Upon Fake NeuroSerge Product Offerings Online

Indeterminate GlobeNewswire

Mar. 31, 2026

Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11

Indeterminate GlobeNewswire